| 2.1399 0.05 (2.39%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.93 | 1-year : | 3.45 |
| Resists | First : | 2.5 | Second : | 2.96 |
| Pivot price | 2.2  |
|||
| Supports | First : | 1.77 | Second : | 1.48 |
| MAs | MA(5) : | 2.11 |
MA(20) : | 2.32 |
| MA(100) : | 7.66 |
MA(250) : | 17.81 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 30.1 |
D(3) : | 29.8 |
| RSI | RSI(14): 40.2 |
|||
| 52-week | High : | 39 | Low : | 1.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ REVB ] has closed above bottom band by 42.4%. Bollinger Bands are 81.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 44 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.16 - 2.17 | 2.17 - 2.18 |
| Low: | 2.01 - 2.02 | 2.02 - 2.03 |
| Close: | 2.13 - 2.14 | 2.14 - 2.16 |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Fri, 22 Mar 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 - Business Wire
Fri, 15 Mar 2024
Is Revelation Biosciences Inc (REVB) a Smart Choice in Biotechnology Friday? - InvestorsObserver
Tue, 12 Mar 2024
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference - Business Wire
Mon, 11 Mar 2024
Should You Buy Revelation Biosciences Inc (REVB) Stock Monday Morning? - InvestorsObserver
Fri, 08 Mar 2024
Where Will Revelation Biosciences Inc (REVB) Stock Go Next After It Is Lower By 7.14% in a Week? - InvestorsObserver
Mon, 05 Feb 2024
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 48 (K) |
| EPS | -0.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -61.1 % |
| Return on Equity (ttm) | -3.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -4.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|